Evaluation of the role of Nrf2/Keap1 pathway‑associated novel mutations and gene expression on antioxidant status in patients with deep vein thrombosis

Akin‑Bali,Di̇lara Fatma; Eroglu,Tamer; Ilk,Sedef; Egi̇n,Yonca; Kankilic,Teoman

doi:10.3892/etm.2020.8790

Evaluation of the role of Nrf2/Keap1 pathway‑associated novel mutations and gene expression on antioxidant status in patients with deep vein thrombosis

Authors:
- Di̇lara Fatma Akin‑Bali
- Tamer Eroglu
- Sedef Ilk
- Yonca Egi̇n
- Teoman Kankilic
View Affiliations

Affiliations: Department of Medical Biology, Faculty of Medicine, Nigde Omer Halisdemir University, 51240 Nigde, Turkey, Department of Cardiovascular Surgery, Faculty of Medicine, Nigde Omer Halisdemir University, 51240 Nigde, Turkey, Department of Immunology, Faculty of Medicine, Nigde Omer Halisdemir University, 51240 Nigde, Turkey, Department of Pediatric Molecular Genetics, Faculty of Medicine, Ankara University, 06100 Ankara, Turkey, Department of Biotechnology, Faculty of Science Literature, Nigde Omer Halisdemir University, 51240 Nigde, Turkey
Published online on: May 25, 2020 https://doi.org/10.3892/etm.2020.8790
Pages: 868-881
Copyright: © Akin‑Bali et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deep vein thrombosis (DVT) is a type of venous thromboembolism and a clinically complex vascular disease. Oxidative stress serves a key role in the pathogenesis of numerous cardiovascular diseases, particularly in endothelial dysfunction‑associated syndromes. Nuclear factor erythroid‑2‑like 2(Nrf2) transcription factor is the primary regulator of antioxidant responses. The levels of reactive oxygen species (ROS) are regulated by Nrf2 and its suppressor protein Kelch‑like ECH‑associated protein 1 (Keap1). However, to the best of our knowledge, genetic abnormalites in the Nrf2/Keap1 pathway in DVT syndrome have not been thoroughly investigated. The aim of the present study was to investigate the association between the Nrf2/Keap1 pathway and antioxidant responses in DVT. Mutations and expression levels of genes involved in the Nrf2/Keap1 pathway were measured in 27 patients with DVT via DNA sequencing analysis and reverse transcription‑quantitative PCR, respectively. The Polymorphism Phenotyping v2 program was used to identify the pathogenic mutations. Total antioxidant activity levels were determined by measuring the effect of serum samples from 27 patients with DVT on oxidation of the 2,2'‑azino‑bis (3‑ethylbenz‑thiazoline‑6‑sulfonic acid) system. A total of 23 mutations, including seven novel mutations, were detected in the Nrf2/Keap1 pathway in 24 (89%) of the 27 patients with DVT. Keap1 mRNA expression levels were significantly higher compared with Nrf2 expression levels in patients with DVT (P=0.02). Analysis of molecular characteristics and gene expression levels demonstrated that Nrf2/Keap1‑associated mutations and total antioxidant levels can be used as precursor markers in the diagnosis of DVT.

View Figures

View References

1	Chistiakov DA, Orekhov AN and Bobryshev YV: Endothelial Barrier and Its Abnormalities in Cardiovascular Disease. Front Physiol. 6(365)2015.PubMed/NCBI View Article : Google Scholar
2	Förstermann U: Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 5:338–349. 2008.PubMed/NCBI View Article : Google Scholar
3	Loscalzo J: Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb. 32:359–360. 2002.PubMed/NCBI View Article : Google Scholar
4	Chen B, Lu Y, Chen Y and Cheng J: The role of Nrf2 in oxidative stress-induced endothelial injuries. J Endocrinol. 225:R83–R99. 2015.PubMed/NCBI View Article : Google Scholar
5	Konukoglu D and Uzun H: Endothelial dysfunction and hypertension. Adv Exp Med Biol. 956:511–540. 2017.PubMed/NCBI View Article : Google Scholar
6	Bengisun U: Basic treatment principles of deep vein thrombosis and pulmonary embolism. TOTBID Derg. 18:505–513. 2019.
7	Kruger PC, Eikelboom JW, Douketis JD and Hankey GJ: Deep vein thrombosis: Update on diagnosis and management. Med J Aust. 210:516–524. 2019.PubMed/NCBI View Article : Google Scholar
8	Harrison D, Griendling KK, Landmesser U, Hornig B and Drexler H: Role of oxidative stress in atherosclerosis. Am J Cardiol. 91 (3A):7A–11A. 2003.PubMed/NCBI View Article : Google Scholar
9	Harrison DG, Gongora MC, Guzik TJ and Widder J: Oxidative stress and hypertension. J Am Soc Hypertens. 1:30–44. 2007.PubMed/NCBI View Article : Google Scholar
10	Howden R: Nrf2 and cardiovascular defense. Oxid Med Cell Longev. 2013(104308)2013.PubMed/NCBI View Article : Google Scholar
11	Park JG and Oh GT: The role of peroxidases in the pathogenesis of atherosclerosis. BMB Rep. 44:497–505. 2011.PubMed/NCBI View Article : Google Scholar
12	da Costa RM, Rodrigues D, Pereira CA, Silva JF, Alves JV, Lobato NS and Tostes RC: Nrf2 as a Potential Mediator of Cardiovascular Risk in Metabolic Diseases. Front Pharmacol. 10(382)2019.PubMed/NCBI View Article : Google Scholar
13	Galley JC and Straub AC: Redox control of vascular function. Arterioscler Thromb Vasc Biol. 37:e178–e184. 2017.PubMed/NCBI View Article : Google Scholar
14	Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ and Johnson JA: Nrf2, a multi-organ protector? FASEB J. 19:1061–1066. 2005.PubMed/NCBI View Article : Google Scholar
15	Smith RE, Tran K, Smith CC, McDonald M, Shejwalkar P and Hara K: The Role of the Nrf2/ARE antioxidant system in preventing cardiovascular diseases. Diseases. 4(34)2016.PubMed/NCBI View Article : Google Scholar
16	Kim J, Cha YN and Surh YJ: A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res. 690:12–23. 2010.PubMed/NCBI View Article : Google Scholar
17	Kaspar JW, Niture SK and Jaiswal AK: Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 47:1304–1309. 2009.PubMed/NCBI View Article : Google Scholar
18	Kansanen E, Kuosmanen SM, Leinonen H and Levonen AL: The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 1:45–49. 2013.PubMed/NCBI View Article : Google Scholar
19	Baird L and Dinkova-Kostova AT: The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 85:241–272. 2011.PubMed/NCBI View Article : Google Scholar
20	Hua CC, Chang LC, Tseng JC, Chu CM, Liu YC and Shieh WB: Functional haplotypes in the promoter region of transcription factor Nrf2 in chronic obstructive pulmonary disease. Dis Markers. 28:185–193. 2010.PubMed/NCBI View Article : Google Scholar
21	Kensler TW, Wakabayashi N and Biswal S: Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89–116. 2007.PubMed/NCBI View Article : Google Scholar
22	Robledinos-Antón N, Fernández-Ginés R, Manda G and Cuadrado A: Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019(9372182)2019.PubMed/NCBI View Article : Google Scholar
23	Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT and Hayes JD: Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 88 (Pt B):108–146. 2015.PubMed/NCBI View Article : Google Scholar
24	Tu W, Wang H, Li S, Liu Q and Sha H: The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases. Aging Dis. 10:637–651. 2019.PubMed/NCBI View Article : Google Scholar
25	Satta S, Mahmoud AM, Wilkinson FL, Yvonne Alexander M and White SJ: The role of Nrf2 in cardiovascular function and disease. Oxid Med Cell Longev. 2017(9237263)2017.PubMed/NCBI View Article : Google Scholar
26	Sarutipaiboon I, Settasatian N, Komanasin N, Kukongwiriyapan U, Sawanyawisuth K, Intharaphet P, Senthong V and Settasatian C: Association of Genetic Variations in NRF2, NQO1, HMOX1, and MT with severity of coronary artery disease and related risk factors. Cardiovasc Toxicol. 20:176–189. 2020.PubMed/NCBI View Article : Google Scholar
27	Korytina GF, Akhmadishina LZ, Aznabaeva YG, Kochetova OV, Zagidullin NS, Kzhyshkowska JG, Zagidullin SZ and Viktorova TV: Associations of the NRF2/KEAP1 pathway and antioxidant defense gene polymorphisms with chronic obstructive pulmonary disease. Gene. 692:102–112. 2019.PubMed/NCBI View Article : Google Scholar
28	Barančík M, Grešová L, Barteková M and Dovinová I: Nrf2 as a key player of redox regulation in cardiovascular diseases. Physiol Res. 65 (Suppl 1):S1–S10. 2016.PubMed/NCBI View Article : Google Scholar
29	Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, Bennett R, Bhai J, Billis K, Boddu S, et al: Ensembl 2019. Nucleic Acids Res. 47 (D1):D745–D751. 2019.PubMed/NCBI View Article : Google Scholar
30	Adzhubei I, Jordan DM and Sunyaev SR: Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 7:7–20. 2013.PubMed/NCBI View Article : Google Scholar
31	Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, et al: COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47 (D1):D941–D947. 2019.PubMed/NCBI View Article : Google Scholar
32	Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, Hussain M, Phillips AD and Cooper DN: The Human Gene Mutation Database: Towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 136:665–677. 2017.PubMed/NCBI View Article : Google Scholar
33	Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M and Rozen SG: Primer3--new capabilities and interfaces. Nucleic Acids Res. 40(e115)2012.PubMed/NCBI View Article : Google Scholar
34	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29(e45)2001.PubMed/NCBI View Article : Google Scholar
35	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
36	World Health Organization (WHO): Cardiovascular diseases (CVDs). WHO, Geneva, 2017. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed May 17, 2017.
37	Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, et al: ISTH Steering Committee for World Thrombosis Day: Thrombosis: A major contributor to global disease burden. Thromb Res. 134:931–938. 2014.PubMed/NCBI View Article : Google Scholar
38	Heitzer T, Schlinzig T, Krohn K, Meinertz T and Münzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 104:2673–2678. 2001.PubMed/NCBI View Article : Google Scholar
39	Suzuki T and Yamamoto M: Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med. 88 (Pt B):93–100. 2015.PubMed/NCBI View Article : Google Scholar
40	Barrera-Rodríguez R: Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? Biomed Rep. 9:375–382. 2018.PubMed/NCBI View Article : Google Scholar
41	Li C, Cheng L, Wu H, He P, Zhang Y, Yang Y, Chen J and Chen M: Activation of the KEAP1-NRF2-ARE signaling pathway reduces oxidative stress in Hep2 cells. Mol Med Rep. 18:2541–2550. 2018.PubMed/NCBI View Article : Google Scholar
42	Surh YJ, Kundu JK and Na HK: Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 74:1526–1539. 2008.PubMed/NCBI View Article : Google Scholar
43	Vanhoutte PM, Shimokawa H, Feletou M and Tang EH: Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 219:22–96. 2017.PubMed/NCBI View Article : Google Scholar
44	Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, Yamamoto M, Kensler TW, Tuder RM, Georas SN, et al: Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med. 202:47–59. 2005.PubMed/NCBI View Article : Google Scholar
45	Kobayashi E, Suzuki T and Yamamoto M: Roles nrf2 plays in myeloid cells and related disorders. Oxid Med Cell Longev. 2013(529219)2013.PubMed/NCBI View Article : Google Scholar
46	Pandey P, Singh AK, Singh M, Tewari M, Shukla HS and Gambhir IS: The see-saw of Keap1-Nrf2 pathway in cancer. Crit Rev Oncol Hematol. 116:89–98. 2017.PubMed/NCBI View Article : Google Scholar
47	Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL and Cannistra SA: Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 71:5081–5089. 2011.PubMed/NCBI View Article : Google Scholar
48	Qin JJ, Cheng XD, Zhang J and Zhang WD: Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: A systematic review. Cell Commun Signal. 17(121)2019.PubMed/NCBI View Article : Google Scholar
49	Silva-Palacios A, Königsberg M and Zazueta C: Nrf2 signaling and redox homeostasis in the aging heart: A potential target to prevent cardiovascular diseases? Ageing Res Rev. 26:81–95. 2016.PubMed/NCBI View Article : Google Scholar
50	Nioi P, Nguyen T, Sherratt PJ and Pickett CB: The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol. 25:10895–10906. 2005.PubMed/NCBI View Article : Google Scholar
51	Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P and Kensler TW: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA. 98:3410–3415. 2001.PubMed/NCBI View Article : Google Scholar
52	Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K and Yamamoto M: Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol. 173:154–160. 2001.PubMed/NCBI View Article : Google Scholar
53	Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T and Yamamoto M: High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci. 59:169–177. 2001.PubMed/NCBI View Article : Google Scholar
54	Kim M, Kim S, Lim JH, Lee C, Choi HC and Woo CH: Laminar flow activation of ERK5 protein in vascular endothelium leads to atheroprotective effect via NF-E2-related factor 2 (Nrf2) activation. J Biol Chem. 287:40722–40731. 2012.PubMed/NCBI View Article : Google Scholar
55	Sihvola V and Levonen AL: Keap1 as the redox sensor of the antioxidant response. Arch Biochem Biophys. 617:94–100. 2017.PubMed/NCBI View Article : Google Scholar
56	Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M and Talalay P: Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA. 99:11908–11913. 2002.PubMed/NCBI View Article : Google Scholar
57	Schmidt H, Hangmann J, Shams I, Avivi A and Hankeln T: Molecular evolution of antioxidant and hypoxia response in long-lived, cancer-resistant blind mole rats: The Nrf2-Keap1 pathway. Gene. 577:293–298. 2016.PubMed/NCBI View Article : Google Scholar
58	Taguchi K, Motohashi H and Yamamoto M: Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells. 16:123–140. 2011.PubMed/NCBI View Article : Google Scholar